Recent Updates
Recently added Catalysts

Casodex

Phase 1

Healthy | Small molecule | Other |Teva Pharmaceutical Industries Limited|Last Updated: Sep 9, 2009

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials2
Total Enrollment120
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00972855Study of Bicalutamide 1 x 50 mg Tablet in Healthy Subjects Under Fed ConditionsPHASE1 COMPLETED 60Sep 1, 2003Sep 1, 2003Sep 9, 20091 Canada
NCT00973050Study of Bicalutamide 1 x 50 mg Tablet in Healthy Subjects Under Fasting ConditionsPHASE1 COMPLETED 60Sep 1, 2003Sep 1, 2003Sep 9, 20091 Canada
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Cmax - Maximum Observed Concentration
Blood samples collected over 72 hour period
AUC0-72 - Area under the concentration-time curve from time zero to 72 hours post dose
Blood samples collected over 72 hour period
AUC0-72: Area under the concentration-time curve from time zero to 72 hours post-dose.
Blood samples collected over 72 hour period
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
Treatment Arms
ArmTypeDescription
BicalutamideEXPERIMENTALBicalutamide 50 mg Tablet
Casodex®ACTIVE_COMPARATORCasodex® 50 mg Tablet
Bicalutamide (test)EXPERIMENTALBicalutamide Tablet, 50 mg
Casodex® (reference)ACTIVE_COMPARATORCasodex® Tablet, 50 mg
Interventions
NameTypeDescription
BicalutamideDRUG50 mg Tablet
Casodex®DRUG50 mg Tablet
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Subjects will be males, non-smokers, 18 years of age and older. Exclusion Criteria: Subjects to whom any of the following applies will be excluded from the study: * Clinically significant illnesses within 4 weeks of the administration of study medication. * Clinically signi...

Countries:Canada
Unlock Eligibility Criteria